How pharmacy acquisition finance works
Pharmacy lending for an acquisition is commercial finance structured around the recurring NHS contract income and covenanted on the deal; it isn't underwritten like a standard retail loan. The numbers depend on the lender and the deal, so what follows is the mechanics, at method level: what a lender is testing and why, before you approach one. For the prior question of whether you can afford the purchase at all, see the companion post on first-time pharmacy buyer finance and affordability.
The fundamental difference from a generic business loan is that a dispensing pharmacy earns its core income under the Community Pharmacy Contractual Framework: reimbursement for dispensing plus remuneration for services. That income is contract-driven and recurring in a way a shop's takings aren't, and that's the case your pharmacy finance application rests on.
Loan structure at method level: term, security, and guarantees
Pharmacy acquisition finance is specialist commercial lending. The structure of any facility will depend on the lender, the deal, and the buyer's financial position. What follows is the main structural features at method level; no rates, loan-to-value ratios, or term lengths are stated here because those are lender-specific and change with market conditions.
Security
Ask early what security the lender wants, because it'll follow the structure. In a share purchase it can sit over the shares and over the underlying business assets as well; in an asset purchase it attaches to the acquired assets directly. The choice of deal structure changes the security picture, which is one of several reasons the share-versus-asset decision matters before any lender conversation starts. The full structuring comparison is covered in the share versus asset purchase guide.
Personal guarantees
If you're a first-time pharmacy buyer, ask whether the lender wants a personal guarantee alongside the company or partnership borrowing. A guarantee means the individual borrower (or guarantors) stands behind the debt if the business can't service it. The scope and terms vary by lender and deal, and a request for one isn't on its own a sign the lender doubts the deal.
What the lender is not doing
A pharmacy acquisition lender is not writing a retail mortgage secured on bricks and mortar as the primary underwriting story. The NHS contract, the dispensing volume, and the adjusted EBITDA carry the underwriting case. Goodwill dominates pharmacy pricing (it is the NHS contract and item volume the buyer is acquiring), but goodwill is intangible. That is why lenders focus on the income the goodwill produces, not the balance-sheet value of the goodwill itself.
What a covenant is, and why lenders use them
A financial covenant is a contractual condition written into the loan agreement that the borrower must satisfy on an ongoing basis throughout the loan term, not just at drawdown. Covenants are the lender's mechanism for monitoring the health of the business that is servicing the debt, between the point of lending and the point of repayment.
For a pharmacy acquisition, these are the covenant types to understand:
| Covenant type | What it tests in plain English | Pharmacy-specific angle |
|---|---|---|
| EBITDA covenant | Earnings before interest, tax, depreciation and amortisation must stay above a minimum level set by the lender | Directly linked to how the pharmacy was valued; the lender is checking that the income surplus that justified the purchase price is still there |
| Debt service cover ratio | Cash available to service debt (capital and interest) as a multiple of the annual debt service obligation | Sensitive to Drug Tariff margin movements because gross margin is set centrally and Category M prices change each quarter |
| Leverage covenant | Total debt as a ratio of EBITDA; controls how loaded the business is | Relevant where the buyer is funding working capital as well as the acquisition, or where a staged payment structure exists |
| Minimum income / turnover | NHS dispensing turnover must not fall below a threshold | Item volume is the underlying driver; a contract variation or significant patient list movement affects this covenant directly |
Specific ratios and thresholds are lender-specific. The table describes the types and their pharmacy logic, not the numbers a particular lender would set. To see how cover is worked, take the example figures in our pharmacy purchase affordability calculator: a £300,000 loan over 25 years at 6.5% costs about £2,026 a month, or £24,307 a year. A company with £60,000 of profit before interest and tax deducts the first year's interest (£19,354) before corporation tax, so the tax is £7,723 at 19% and £52,277 is left to meet the repayments: cover of 2.15x. That's the tool's own example, not a lender's test, and your lender may measure cover differently, so ask which ratio it tests and how.
Covenants are tested on a schedule the facility agreement sets, such as quarterly or annually, based on the management accounts or the filed accounts. Lenders may also include information covenants requiring the borrower to deliver accounts, dispensing data, or other management information within agreed timeframes. Missing an information covenant is itself a breach even if the financial numbers are healthy.
The EBITDA covenant explained
EBITDA (earnings before interest, tax, depreciation and amortisation) makes a natural covenant anchor in pharmacy acquisition lending, because pharmacies are priced on a multiple of adjusted EBITDA and it's how debt-service capacity was projected when the lender approved the loan.
What EBITDA measures
EBITDA strips out the financing structure (interest), the tax position, and the non-cash charges (depreciation and amortisation) to give a measure of operating earnings from the business itself. For a dispensing pharmacy, those operating earnings are driven by the NHS contract income after staff, premises, and operating costs.
Why "adjusted" EBITDA matters in a pharmacy deal
Raw EBITDA from the accounts may not reflect the true earning capacity of the pharmacy on an arm's-length basis. Adjustments can include:
- Adding back an owner's salary above a market-rate management cost (because the buyer is paying themselves differently from the selling owner).
- Removing one-off costs or income that will not recur under new ownership.
- Normalising for any period where the previous owner's health or absence suppressed item volume.
- Stripping out costs the seller was running through the business that the buyer will not.
The adjusted EBITDA is the number you and your specialist adviser present to a lender as the verified income surplus. It's also the number that underpins the valuation methodology (valuation stays method-level, on a multiple of adjusted EBITDA and pence-per-item; no specific multiple is quoted here because the multiple is deal-specific and lender-specific).
The link between valuation and covenant is direct: if the lender valued the lending on an adjusted EBITDA multiple, the EBITDA covenant protects the same metric throughout the loan term. A fall in adjusted EBITDA means the business would be worth less under the same multiple, so the lender's security position has weakened.
The covenant threshold
The covenant threshold (the minimum EBITDA level you must maintain) is set by the lender at the time of lending and will be stated in the facility agreement. It is not a published industry standard and varies by lender, deal size, and the lender's assessment of the income risk in this particular pharmacy.
What happens if the covenant is breached
A covenant breach triggers a notification obligation to the lender and a conversation. The outcome depends on the facility agreement and the lender's assessment of the cause. The responses it can lead to include:
- Waiver: the lender waives the breach for a defined period, and may attach conditions.
- Remedy period: the borrower is given time to restore the metric, and may have to provide a plan.
- Margin step-up: the interest margin increases as a cost of breach.
- Accelerated repayment: in persistent or material cases, the lender may call in the facility early.
The practical risk in a pharmacy is that a lower quarter's Category M prices, or a Drug Tariff change, suppress gross margin in a quarter where income and costs are otherwise stable. That is why monitoring covenant headroom throughout the year (not just at year-end) is part of the ongoing financial management of the acquisition.
How the NHS income and margin story shape lender appetite
Here's what to put in front of a lender for a pharmacy, set against the figures a general business loan starts from:
| What a generic business lender might look at | What a pharmacy acquisition lender reads instead | Why it matters |
|---|---|---|
| Total sales turnover from the till | NHS contract income: reimbursement plus remuneration under the CPCF | Pharmacy income is contract-driven, not till-driven; NHS income is recurring and regulated in a way retail sales are not |
| Year-end accounts gross profit | Adjusted EBITDA, with Drug Tariff and Category M adjustments normalised | Gross margin is set centrally through the Drug Tariff, with Category M prices reset each quarter; the reported margin in any single year may not reflect the normalised position |
| Current-year cash position | FP34 payment cycle: NHSBSA's 100% advance and the reconciliation | Prescriptions are declared monthly; the estimated advance arrives around the 10th of the next month and the reconciliation two months after submission; the gap is structural, not a sign of cash weakness |
| VAT-inclusive retail revenue | VAT-split income: zero-rated dispensing versus standard-rated OTC and services | The pharmacy is a VAT-mixed business; reading VAT-inclusive revenue as a single number distorts the real income picture for both lender and buyer |
| Item-level retail data | Dispensing item volume over time (monthly, quarterly, year-on-year) | Item volume drives reimbursement income and benchmarks the pharmacy's NHS contract utilisation; a declining item trend signals contract and covenant risk |
Service income under Pharmacy First and similar schemes is a separately accounted revenue line; from 2026/27 the Pharmacy First budget sits inside the contract's £3.636 billion. Ask your lender how it treats service income, because it may be weighted differently from core dispensing income in covenant calculations.
Finance-ready accounts and covenant headroom
The quality of the accounts you bring to a lender conversation determines how much uncertainty the lender builds into its covenant thresholds. Poor-quality accounts (NHS income mixed with OTC retail, Drug Tariff adjustments not reconciled, VAT mix unclear) force the lender to apply conservative assumptions, which can mean tighter covenant headroom than the business's actual position warrants.
Finance-ready accounts for a pharmacy acquisition do the following:
- Separate NHS reimbursement income from OTC retail so the contract-driven recurring income line is clearly evidenced.
- Reconcile NHSBSA payments to the FP34 submissions for each period, showing each advance and the reconciliation that follows it.
- Show margin quarter by quarter, so the effect of each Category M price change is visible, and match each reconciliation to the month it relates to, not the month the payment lands.
- Present the VAT-mixed position correctly, distinguishing zero-rated dispensing from standard-rated sales.
- Calculate adjusted EBITDA with documented add-backs, consistent across all periods presented to the lender.
The same accounts structure that makes a lender confident at drawdown also makes covenant monitoring straightforward throughout the loan term. When the lender tests your EBITDA covenant from the management accounts, the calculation should be reproducible from the same methodology used at inception. Inconsistency between periods is something a lender can fairly read as a covenant risk in itself.
The companion post on first-time pharmacy buyer finance and affordability covers the deposit, loan, and post-tax cash-cover arithmetic that sits before the lender conversation. That affordability arithmetic feeds into the same adjusted EBITDA that a covenant will later test.
The pharmacy purchase affordability calculator models the scenario in structured form as an estimate. It is a starting point for the specialist review, not a lending decision.
If you are approaching the purchase of a pharmacy and want a clear picture of how the financial due-diligence process fits alongside the loan mechanics, the pharmacy financial due diligence guide covers that in detail.
Add the purchase price, deposit, loan terms and projected profit to see the monthly repayment, the post-tax cash cover and the stamp duty or SDLT on a share deal against an asset deal.
Pharmacy Purchase Affordability Calculator
Enter the purchase price, deposit, loan terms and projected pharmacy profit to see your estimated loan repayments, how well trading cash flow covers the debt, and the acquisition tax cost for a share deal versus an asset deal. Every figure already in the boxes is an example, so replace it with your own; the result on your deal depends on how it's structured.
The agreed headline price for the pharmacy. Enter the actual figure from your heads of terms.
The amount you are putting in from your own funds. The rest is assumed to be financed by a commercial loan.
The term your lender offers. Shorter terms mean higher repayments but less total interest.
The rate quoted by the lender. The rate you are offered depends on lender, term and loan-to-value.
The part of the price that buys land or buildings: a freehold, or what you pay for a lease. Leave at 0 if no property is being bought. SDLT is charged on this figure only, never on goodwill or the NHS contract.
Only if you're taking a new lease of the premises. SDLT is due on the rent's net present value at 1% from £150,001 to £5 million and 2% above. HMRC's SDLT calculator works the figure out from the rent and the term.
The adjusted EBITDA or trading profit you expect after your salary, before loan interest and tax. The tool takes the first year's interest off before working out corporation tax.
Your result
Your answer's ready. Press below to see it.
What a specialist prepares before you approach a lender
Approaching a pharmacy acquisition lender without finance-ready accounts and a clear adjusted EBITDA analysis puts the buyer in a weak negotiating position. The lender's questions about covenant structure are directly driven by the clarity of the information pack. A well-prepared pack reduces lender uncertainty, and that's the lever you control before the rate and covenant negotiation starts.
Before any lender conversation, a specialist will prepare:
- A reconciled income analysis separating NHS contract income from retail, with NHSBSA payment data matched to FP34 submissions.
- An adjusted EBITDA calculation with documented add-backs for owner-specific costs, one-off items, and Drug Tariff timing differences, consistent across at least three years of accounts.
- A working-capital model that covers the stock and wages you pay in the first months of ownership before each NHSBSA advance lands.
- A VAT-mix summary evidencing the zero-rated dispensing proportion, the standard-rated OTC and service income split, and the input VAT reclaim position.
- A covenant sensitivity analysis showing how much the EBITDA can fall before the proposed covenant threshold is breached, and what margin volatility scenarios (Drug Tariff adjustments, item volume movements) could get there.
These loan mechanics are for a dispensing pharmacy in England, where the NHS contract terms (CPCF, the Drug Tariff's payment timetable, Pharmacy First) apply. Scotland, Wales and Northern Ireland have their own pharmacy contracts, so check the income terms there before you rely on any of this.
For help preparing the accounts and adjusted EBITDA analysis before a lender conversation, see the pharmacy purchase accounting service or talk to us via the buying a pharmacy hub.
Want this checked against your specific situation?
Leave your details and a one-line summary. One of our specialists will come back to you, with no obligation.